Aneurysm Surgery — Cost, Top Hospitals & Success Rates | MyMedicPlus

Aneurysm surgery encompasses the surgical and endovascular interventions used to treat pathological dilatations of blood vessel walls — aneurysms — that carry a risk of rupture, thrombosis, or embolisation. An aneurysm is defined as a permanent localised dilatation of a vessel to more than 1.5 times its normal diameter, caused by weakening of the vessel wall from atherosclerosis, genetic predisposition, infection, or trauma. The two most clinically important sites are the aorta (particularly the infrarenal abdominal aortic aneurysm, or AAA) and the cerebral vasculature (intracranial saccular aneurysms, the cause of most non-traumatic subarachnoid haemorrhage).

The decision to intervene surgically on an aneurysm is governed by the risk of rupture without treatment weighed against the procedural mortality and morbidity. For abdominal aortic aneurysms, intervention is typically recommended when the diameter exceeds 5.5 cm in men (5.0–5.5 cm in women), or when growth exceeds 1 cm per year. Ruptured AAA carries an overall mortality of 80–85%; elective repair has a mortality of 1–3% for endovascular repair and 3–5% for open surgery.

Surgical approaches have been transformed by endovascular technology. Endovascular aneurysm repair (EVAR) for aortic aneurysms involves deployment of a stent-graft through the femoral arteries under fluoroscopic guidance, excluding the aneurysm sac from the circulation without open surgery. For intracranial aneurysms, endovascular coiling has largely replaced open neurosurgical clipping as the preferred primary treatment in most centres, based on results from the landmark ISAT trial.

Abdominal aortic aneurysm (AAA) — the most common large-vessel aneurysm, occurring in approximately 4–8% of men over 65 and 1% of women — is treated by elective EVAR or open surgical repair when threshold size criteria are met. Thoracic aortic aneurysm (TAA) and thoracoabdominal aortic aneurysm (TAAA), involving the ascending and/or descending thoracic aorta, are treated by thoracic EVAR (TEVAR) or complex open surgery via thoracotomy. Aortic aneurysms in the context of connective tissue disorders (Marfan syndrome, Ehlers-Danlos syndrome, Loeys-Dietz syndrome) require earlier intervention at smaller diameters due to higher rupture risk.

Intracranial (cerebral) aneurysms are treated by endovascular coiling (detachable platinum coils deployed via microcatheter), surgical clipping (a metallic clip applied across the aneurysm neck via craniotomy), or flow diversion (pipeline embolisation device). The choice depends on aneurysm morphology, location, size, and patient characteristics. Peripheral aneurysms — popliteal, femoral, splenic — are treated surgically due to their embolic and thrombotic risks rather than rupture risk.

Patients with asymptomatic AAA below the threshold diameter (less than 5.5 cm in men) are managed by surveillance ultrasound every 1–3 years and cardiovascular risk factor optimisation. Symptomatic AAA (abdominal or back pain attributable to the aneurysm) warrants urgent surgical evaluation regardless of size. Ruptured AAA is a surgical emergency. Fitness for surgery is assessed using cardiopulmonary exercise testing, echocardiography, and pulmonary function tests; patients deemed high-risk for open surgery are preferentially offered EVAR if anatomy allows.

For cerebral aneurysms, management decisions weigh rupture risk (based on size, location, morphology, patient factors) against procedural risk. Unruptured aneurysms smaller than 7 mm in patients without prior subarachnoid haemorrhage have a very low 5-year rupture risk (approximately 0.5%) and are often managed conservatively with surveillance MRA. Contraindications to EVAR include unfavourable aortic neck anatomy, inadequate femoral access vessels, and contrast allergy; these patients require open repair or specialised EVAR techniques.

Endovascular aneurysm repair (EVAR) for AAA involves percutaneous or cut-down access to the femoral arteries, delivery of a bifurcated stent-graft device under fluoroscopic guidance, and exclusion of the aneurysm sac. EVAR has lower 30-day mortality (0.5–1.6%) and shorter hospital stay (2–3 days) than open repair but requires life-long surveillance for endoleak and potential secondary interventions. Approximately 40–60% of AAAs are anatomically suitable for EVAR.

Open surgical repair of AAA involves midline laparotomy or retroperitoneal approach, cross-clamping of the aorta, and replacement of the aneurysmal segment with a synthetic Dacron graft. Despite higher perioperative morbidity than EVAR, open repair provides durable long-term results without endoleak risk and is preferred in younger patients (under 65) with good fitness. For cerebral aneurysms, endovascular coiling achieves aneurysm occlusion in approximately 85–90% of cases, while neurosurgical clipping via craniotomy provides definitive neck occlusion particularly for wide-neck or mid-cerebral artery aneurysms. Flow diversion (pipeline device) is increasingly used for large fusiform intracranial aneurysms not amenable to coiling or clipping.

Selecting the most appropriate Aneurysm Surgery approach requires a structured assessment of patient-specific factors. The treating specialist evaluates disease severity, prior treatment history, comorbidities, and patient preferences before recommending a specific protocol. Combination approaches are often more effective than monotherapy — integrating pharmacological, procedural, or rehabilitative elements to address multiple disease mechanisms simultaneously. Dose or intensity is titrated incrementally based on clinical response, tolerability, and objective outcome measures. In patients with refractory disease or inadequate response to first-line protocols, escalation to higher-intensity or specialist-delivered treatment options is indicated. Multidisciplinary team (MDT) review ensures that surgical, medical, and allied health perspectives are integrated into the final management plan, particularly for complex or high-risk cases where multiple treatment pathways are viable and the risk-benefit balance requires careful deliberation.

Elective repair of AAA eliminates the catastrophic rupture risk that carries 80% mortality. The EVAR-1 and DREAM trials demonstrated that EVAR carries approximately 60–70% lower 30-day mortality compared to open repair (1.6% vs 4.6%), though this benefit narrows at 2 years due to aneurysm-related secondary interventions in the EVAR group. Long-term survival is comparable between the techniques at 5–10 years. EVAR patients have significantly shorter hospital stays (mean 3 days vs 7–10 days for open repair) and faster return to daily activities.

For cerebral aneurysms, the landmark ISAT trial (International Subarachnoid Aneurysm Trial) demonstrated that endovascular coiling of ruptured intracranial aneurysms produces better outcomes at 1 year than neurosurgical clipping, with 23.7% relative risk reduction in dependency or death. Complete occlusion rates for coiling are approximately 80–85% initially, with approximately 20–30% of coiled aneurysms showing recanalisation on long-term follow-up and requiring re-treatment; clipped aneurysms have more durable occlusion. Unruptured aneurysm repair in appropriately selected patients eliminates the anxiety associated with living with a known aneurysm and removes the future rupture risk.

Open AAA repair carries a 30-day mortality of 2–5% in elective cases and is associated with significant perioperative morbidity including myocardial infarction (5–10%), renal impairment (10–15%), pulmonary complications (10–20%), and rarely spinal cord ischaemia (paraplegia, less than 1% for infrarenal repair but higher for thoracoabdominal repairs). Graft complications including infection and graft-enteric fistula are rare but life-threatening long-term sequelae.

EVAR-specific risks include endoleak (inadequate seal between stent-graft and aortic wall, occurring in 10–20% of cases on follow-up), limb occlusion, device migration, and conversion to open repair in 1–3% of cases. Life-long CT surveillance for endoleak is required after EVAR, exposing patients to cumulative radiation. Cerebral aneurysm coiling risks include thromboembolic complications (5%), aneurysm perforation (1–2%), and recanalisation requiring retreatment. Neurosurgical clipping carries risks of craniotomy including cerebral oedema, infection, and a 3–5% risk of neurological deficit.

Recovery after EVAR is typically rapid: patients are usually mobilised the same day or next morning, discharged at 2–3 days, and can return to light activities within 2 weeks and normal activities within 4–6 weeks. CT angiography at 1 month, 6 months, and annually thereafter is standard surveillance for endoleak and graft integrity. Duplex ultrasound surveillance is an alternative in centres with protocols validated for endoleak detection.

Open AAA repair requires 7–10 days hospitalisation and 6–12 weeks convalescence before return to normal activities. Heavy lifting should be avoided for 3 months due to abdominal wound healing. Cardiovascular risk factor optimisation (statin therapy, antiplatelet therapy, blood pressure control, smoking cessation) is essential long-term management for all aneurysm patients. Cerebral aneurysm patients are followed with MRA at 6 months, 18 months, and 5 years after coiling to assess occlusion status and identify recanalisation. Clipped aneurysms generally require less intensive follow-up imaging.

Aneurysm surgery is among the more expensive vascular procedures due to the complexity of the operation and the high cost of endovascular devices. In the United States, elective EVAR costs $50,000–120,000 including device, hospital stay, and professional fees. Open AAA repair costs $30,000–80,000 but with a longer hospital stay. Cerebral aneurysm treatment (coiling or clipping) costs $50,000–150,000 in US hospitals.

For patients travelling for elective aneurysm surgery, India, Thailand, and Turkey offer internationally accredited vascular surgery programmes at substantially lower cost. EVAR in India at JCI-accredited hospitals (Apollo, Fortis, Max Healthcare) costs $8,000–20,000 — a saving of 70–85%. Open AAA repair costs $6,000–15,000. Neurosurgical aneurysm clipping or coiling in India costs $5,000–15,000. These centres use the same imported stent-graft devices (Cook, Medtronic, Gore) as Western hospitals. Pre-operative imaging (CT angiography) can often be arranged locally and sent digitally for review by the surgical team before travel.

For small asymptomatic aneurysms below surgical threshold, surveillance with serial imaging (duplex ultrasound for AAA, MRA for cerebral) is the appropriate management. Cardiovascular risk factor modification — statin therapy (which may slow AAA growth by 1–2 mm/year), antihypertensive therapy, and smoking cessation — is essential for all aneurysm patients regardless of size. The UK Small Aneurysm Trial demonstrated no survival benefit from early surgery for AAA below 5.5 cm.

For cerebral aneurysms, conservative management with surveillance is appropriate for small, incidental, low-risk aneurysms, particularly in elderly patients or those with significant comorbidities where procedural risk outweighs rupture risk. Antihypertensive optimisation reduces pulsatile wall stress. There are currently no pharmacological therapies proven to prevent aneurysm growth or rupture, though research into doxycycline, angiotensin receptor blockers, and statins is ongoing.